Released in May 2026, the Novo Nordisk Q1 2026 report showcases a complex but optimistic financial picture, highlighting a massive revenue beat fueled by the record-breaking U.S. launch of the Wegovy pill, prompting the pharmaceutical giant to raise its full-year guidance.
Novo Nordisk will present 52 abstracts at the European Congress on Obesity, showcasing a portfolio that includes high-dose Wegovy and new data on women’s health during menopause.
The Foundayo launch impact on Eli Lilly has been swift and sharp — while FDA approval of orforglipron marked a historic first for oral GLP-1 obesity treatment, early prescription data trailing Novo Nordisk’s Wegovy sent LLY stock down as much as 4.3%, forcing analysts to slash 2026 revenue forecasts from $5 billion to just $1.3–1.6 billion.
Novo Nordisk has announced breakthrough results from its PIONEER TEENS trial, proving that oral semaglutide for type 2 diabetes in children offers superior glycemic control and a well-tolerated safety profile for adolescents.
Novo Nordisk and OpenAI have announced a historic strategic collaboration to integrate generative AI across R&D, manufacturing, and global operations to bring life-saving treatments to market faster.
New clinical data reveals that oral semaglutide (Wegovy pill) offers greater weight loss efficacy and significantly better GI tolerability than orforglipron.
Novo Nordisk and United Biotechnology announce that their jointly developed UBT251 triple agonist targeting GLP-1, GIP, and glucagon receptors outperformed semaglutide 1 mg in a 24-week Chinese phase 2 trial, setting the stage for global phase 3 development.
FDA warning letter reveals systemic failures in Novo Nordisk’s semaglutide safety reporting. Details on 15-day reporting violations, deaths, and suicides not reported to FDA. Regulatory analysis and consequences.
In a major industry shift, Hims & Hers will ditch compounded GLP-1s to offer branded Wegovy and Ozempic at self-pay prices following a settlement with Novo Nordisk.
Novo Nordisk announced today a significant reduction in US list prices for
Wegovy, Ozempic, and Rybelsus, with prices dropping to $675 per month effective
January 1, 2027. The price cuts approximately 50% for Wegovy and 35% for Ozempic
represent a major step toward improving patient access and affordability for
obesity and type 2 diabetes treatments.
